Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Vasoplegia

In brief

Vasopressors are medications that are given intravenously to increase the blood pressure of patients with illnesses that cause dangerous blood pressure drops. When a doctor prescribes a vasopressor, they ask that the dose be adjusted to achieve a specific blood pressure. This kind of medical support with intravenous (IV) vasopressors are usual treatments in intensive care unit (ICU) settings. Oral vasopressors, such as midodrine, have been historically used to maintain blood pressure in non-critically ill patients. In this study, the investigators will be using midodrine to reduce the need for IV vasopressors as blood pressure improves during the stay in the ICU. This LIBERATE multi-site study will continue the work of the LIBERATE feasibility RCT study to evaluate the role of midodrine for patients with low blood pressure in the ICU. It is comprised of the multi centre pilot RCT followed by the definitive multi centre RCT.

Key facts

Study ID: NCT05058612
Run by: University of Alberta
People needed: 870
Starts: 2021-03-22
Expected to finish: 2028-02-01
Last updated by the study team: 2026-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Age > 18 years
Ongoing vasopressor support
Decreasing vasopressor dose(s)

You may not qualify if…

Greater than 24 hours from peak vasopressor dose
Contraindication to enteral medications
Previously received midodrine in last 7 days
Expected death or anticipated withdrawal of life-sustaining therapies in next 24 hours
Pregnancy
Known allergy to midodrine

Where it is running

University of Alberta Hospital — Edmonton, Alberta, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.